503 related articles for article (PubMed ID: 33297461)
21. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study.
Todsaporn D; Zubenko A; Kartsev V; Aiebchun T; Mahalapbutr P; Petrou A; Geronikaki A; Divaeva L; Chekrisheva V; Yildiz I; Choowongkomon K; Rungrotmongkol T
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049777
[TBL] [Abstract][Full Text] [Related]
23. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
[TBL] [Abstract][Full Text] [Related]
24. BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC).
Patel HM; Shaikh M; Ahmad I; Lokwani D; Surana SJ
J Biomol Struct Dyn; 2021 May; 39(8):2838-2856. PubMed ID: 32276580
[TBL] [Abstract][Full Text] [Related]
25. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
Chen ZW; Lin G; Shih HJ; Wu CE
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
[TBL] [Abstract][Full Text] [Related]
26. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
27. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
[TBL] [Abstract][Full Text] [Related]
28. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
29. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
30. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Uchibori K; Inase N; Araki M; Kamada M; Sato S; Okuno Y; Fujita N; Katayama R
Nat Commun; 2017 Mar; 8():14768. PubMed ID: 28287083
[TBL] [Abstract][Full Text] [Related]
31. Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFR
Xu S; Zhou Z; He J; Guo J; Huang X; An Y; Pan Q; Xu S; Zhu W
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300460. PubMed ID: 38009481
[TBL] [Abstract][Full Text] [Related]
32. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
Zhao P; Yao MY; Zhu SJ; Chen JY; Yun CH
Biochem Biophys Res Commun; 2018 Jul; 502(3):332-337. PubMed ID: 29802850
[TBL] [Abstract][Full Text] [Related]
33. Insights into the Overcoming EGFR
Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
[TBL] [Abstract][Full Text] [Related]
34. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFR
Guo Y; Gao B; Gao P; Wang Y; Gou S
Bioorg Med Chem; 2023 Jul; 90():117338. PubMed ID: 37269687
[TBL] [Abstract][Full Text] [Related]
36. Uncommon de novo EGFR
Pang LL; Zhuang WT; Huang YH; Liao J; Li MZ; Lv Y; Zhang L; Fang WF
Lung Cancer; 2024 Apr; 190():107528. PubMed ID: 38461768
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.
Zhu Y; Ye X; Shen H; Li J; Cai Z; Min W; Hou Y; Dong H; Wu Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2023 Nov; 66(21):14633-14652. PubMed ID: 37885208
[TBL] [Abstract][Full Text] [Related]
38. Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines.
Han C; Ren J; Su F; Hu X; Li M; Wang Z; Wu L
Anticancer Agents Med Chem; 2020; 20(6):724-733. PubMed ID: 32116203
[TBL] [Abstract][Full Text] [Related]
39. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
Engel J; Smith S; Lategahn J; Tumbrink HL; Goebel L; Becker C; Hennes E; Keul M; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Hengstler JG; Rauh D
J Med Chem; 2017 Sep; 60(18):7725-7744. PubMed ID: 28853575
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]